Innovative Strategies for Cancer Care
Innovative Strategies for Cancer Care
As cancer treatment evolves, innovative strategies are crucial for improving patient outcomes. This discussion focuses on AstraZeneca's leading role in advancing oncology through a diversified portfolio, novel therapies, and a commitment to clinical trials. Emphasizing the importance of integrating cutting-edge research and technology in treatment plans ensures better patient support and long-term survival rates in challenging cases.
Innovative Strategies for Cancer Care
@financepresentations1 week ago
Oncology and Haematology
David Fredrickson, EVP, Oncology Business Susan Galbraith, EVP, Oncology R&D Cristian Massacesi, CMO & Oncology Chief Development Officer Anas Younes, SVP, Global Head of Haematology, Oncology R&D Sunil Verma, SVP, Global Medical Affairs Matt Hellmann, VP, Early Oncology Development
Forward looking statements
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected or targeted revenues, margins, earnings per share or other financial or other measures (including the Financial Ambition Statements described in this presentation). Although the Group believes its expectations and targets are based on reasonable assumptions and has used customary forecasting methodologies used in the pharmaceutical industry and risk-adjusted projections for individual medicines (which take into account the probability of success of individual clinical trials, based on industry-wide data for relevant clinical trials at a similar stage of development), any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property-related risks to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; the impact that global and/or geopolitical events may have, or continue to have, on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition There can be no guarantees that the conditions to the closing of the proposed transaction with Fusion will be satisfied on the expected timetable, or at all, or that 'FPI-2265' (Ac225-PSMA I&T) or any combination product will receive the necessary regulatory approvals or prove to be commercially successful if approved. There can be no guarantees that the conditions to the closing of the proposed transaction with Amolyt Pharma will be satisfied on the expected timetable, or at all, or that eneboparatide ('AZP-3601') will receive the necessary regulatory approvals or prove to be commercially successful if approved.
This presentation includes references to new molecular entities and life-cycle management programmes that are being investigated in current or future clinical trials, and as such have not been approved by any regulatory agency. For a list of new molecular entities and indications in development, see pages 7-11 of the Clinical Trials Appendix that accompanied AstraZeneca's Q1 2024 results.
Basis of AstraZeneca ambitions, forecasts and targets
AstraZeneca ambitions, forecasts and targets in this presentation (the 'Financial Ambition Statements') are derived from AstraZeneca's most recent risk-adjusted mid- and long-term plans, adjusted for developments in the business since those plans were finalised. Financial Ambition Statements presented are based on management's risk-adjusted projections for individual medicines and individual clinical trials. Estimates for these probabilities are based on industry-wide data for relevant clinical trials in the pharmaceutical industry at a similar stage of development adjusted for management's view on the risk profile of the specific asset. The peak year revenue (PYR) potential for individual medicines referred to in this presentation are the maximum estimated Total Revenue to be recognised by AstraZeneca in a single calendar year, during the lifecycle of the medicine, and are based on management's latest non-risk adjusted forecast estimates. Estimates are based on customary forecasting methodologies used in the pharmaceutical industry. Peak year revenue may occur in different years for each NME depending on trial outcomes, approval label, competition, launch dates and exclusivity periods, amongst other variables. The peak year revenue figures are derived from net sales at nominal values and are not risk-adjusted or time-value discounted. The development of pharmaceutical products has inherent risks given scientific experimentation and there are a range of possible outcomes in clinical results, safety, efficacy and product labelling. Clinical results may not achieve the desired product profile and competitive environment, pricing and reimbursement may have material impact on commercial revenue forecasts. By their nature, forecasts are based on a multiplicity of assumptions and actual performance in future years may vary, significantly and materially, from these assumptions. The Financial Ambition Statements in this presentation are based on Q1 2024 exchange rates; AZ undertakes no obligation to update those statements based on future currency movements
Unmet need in cancer remains a global challenge
Five million new cancer patients diagnosed globally 1 per year with low 5-year survival
4
Critical trends in transforming cancer treatment
Our strategy to transform patient outcomes
Treat earlier and smarter
6
Powerful combinations to transform survival in cancer
Kill cancer cells, debulk tumour and activate immune system with checkpoint inhibitors
ADCs
IO bispecifics
Radioconjugates
Enhance immune system when checkpoint inhibition alone is insufficient
T-cell engagers
CAR-Ts
Debulk tumour with ADCs or Radioconjugates , clear micro-metastatic disease with cell therapy or T-cell engagers
ADCs and Radioconjugates potential to replace systemic chemotherapy, combine with novel IO bispecifics
PARP1 inhibitors to potentiate clinical benefit of ADCs and Radioconjugates
7
We are leading the ADC revolution to replace systemic chemotherapy
Significant potential ADC opportunity across multiple tumours
Enhertu - leading HER2 ADC with transformational data across multiple tumour types
DESTINY-Breast03 1
HER2+ 2L+ breast cancer
DESTINY-Breast04 2
HER2-low 3L+ breast cancer
DESTINY-Breast06 (HER2-low/ultra-low) - statistically significant, clinically meaningful improvement in PFS 5
1. Hurvitz SA et al. Lancet. 2023 Jan 14;401(10371):105-117. 2. Modi S et al. N Engl J Med. 2022 Jul 7;387(1):9-20. 3. Meric-Bernstam F et al. J Clin Oncol. 2024 Jan 1;42(1):47-58. 4. Solid tumours including endometrial, cervical, ovarian, bladder, BTC, pancreatic. 5. AstraZeneca press release. https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-improved-pfs-in-her2-low-and-ultralow.html. Accessed May 2024. Acronym definitions can be found in Glossary. Collaboration partners: Daiichi Sankyo ( Enhertu ).
DESTINY-PanTumor02 3
HER2+ 2L+ tumours 4
Dato-DXd - potential to displace chemotherapy in NSCLC and breast cancer
1
2
First TROP2 ADC in NSCLC to demonstrate statistically significant, clinically meaningful outcomes in Phase III
Next-generation bispecifics - going beyond PD-1/PD-L1 inhibitors to establish new IO segments
ADC + IO combinations proven to transform outcomes
Breast cancer
Upcoming early-stage data
Early data support strong efficacy and safety in metastatic disease
Lung cancer
We have the right portfolio to lead in ADC + IO combinations
Ongoing novel IO bispecifics + ADC Phase II proof-of-concept data
Illustrative 5-year OS curve
Striving to lift OS curves
Phase II trials ongoing include DESTINY-Lung03, TROPION-Lung04, AstraZeneca Phase I/II first-in-human 1L NSCLC, TROPION-Lung02, TROPION-Lung04, NeoCOAST2.0, DESTINY-Gastric03, GEMINI Gastric, TROPION-PanTumor03, BEGONIA, ISPY2. 1. Data on file, not yet published or presented. Acronym definitions can be found in Glossary.
Our commercial strategy to transform patient outcomes
Medicines that matter
Building transformative brands
Leveraging scale
Tumour area leadership
Transforming patient care
Closing the care gap
Leading in lung cancer today and tomorrow
Oncology and Haematology - next wave of growth to 2030 and beyond
We are investing in clinical trials today for future growth
Significant news flow across key medicines through 2025
2024
2025
Multiple Phase III trial initiations planned with IO bispecifics and ADC combinations over next 12-18 months
